Search results
We demonstrated the successful use of a novel AVP infusion protocol for the management of chronic DI in a. 27-hour facial transplantation surgery. This protocol may also be effective in managing other patients with chronic, unusual, and dificult-to-control DI during lengthy intraop-erative periods.
Diabetes insipidus is treated with demopressin/DDAVP in the following doses: oral or sublingual - 100-200µg (0.1-0.2mg) intranasal spray - 10=20µg. IM or IV injection - 1-2µg.
11 sty 2024 · 1. Arginine Vasopressin Deficiency (AVP-D, formerly known as Central Diabetes Insipidus or CDI) The preferred therapy is DDAVP. Typically, treatment is maintained for AVP-D, which varies depending on the cause. The minimum dose should be administered to control polyuria adequately.
3 kwi 2018 · Objective: Titration of desmopressin can be challenging during complex, lengthy surgical procedures in patients with chronic central diabetes insipidus (DI). Arginine vasopressin (AVP) may be the preferred treatment modality in these settings.
Long-term treatment with desmopressin (dDAVP) can control the thirst and polyuria of CDI and, in the absence of other pituitary hormone deficiencies, can allow the patient a normal quality of life. The dose of dDAVP required is proportional to the degree of AVP deficiency.
Transient pregnancy associated diabetes insipidus is treated with dDAVP, which can usually be withdrawn within 2 months of delivery .
1 wrz 2020 · Oral dDAVP has replaced nasal dDAVP as a more reliable mode of treatment for chronic central diabetes insipidus. Hyponatraemia is a common side effect, occurring in one in four patients, and should be avoided by allowing a regular break from dDAVP to allow a resultant aquaresis.
